Summit Therapeutics Inc. (Nasdaq: SMMT) on June 12, 2026, disclosed its decision to withdraw an underwritten public offering proposed just two days previously, citing adverse market conditions. The cancellation means no securities were sold and no proceeds were raised, leaving the company to rely on existing resources — including an expanded at-the-market facility — to fund its ivonescimab development program.
The withdrawal is notable given Summit's active capital-raising history. Since licensing ivonescimab (SMT112) from China-based Akeso in December 2022, Summit has completed a USD 200 million public equity offering in June 2024 and a USD 500 million private placement in 2025, in addition to expanding its ATM facility by approximately USD 360 million in August 2025. The failed June 2026 offering suggests that market conditions at the time of launch did not support the pricing or size management sought, a dynamic that has affected multiple clinical-stage oncology companies in recent quarters.
Summit is built almost entirely around ivonescimab, a bispecific antibody that simultaneously blocks PD-1 and VEGF signaling. The dual-blockade mechanism is designed to combine checkpoint inhibition with anti-angiogenic activity in a single molecule, potentially offering advantages over sequential or combination use of separate agents. Akeso, which retains rights in China and select other markets, has reported statistically significant progression-free survival data for ivonescimab versus pembrolizumab in PD-L1-high non-small cell lung cancer — results that generated substantial investor interest in Summit's licensed territories, which cover the US, Canada, Europe, Japan, Latin America, the Middle East, and Africa following a June 2024 territory expansion.